comparemela.com

Latest Breaking News On - Anders ullman - Page 2 : comparemela.com

Swedish Orphan Biovitrum AB: Bulletin from Swedish Orphan Biovitrum (Sobi) s Annual General Meeting (AGM)

STOCKHOLM, May 9, 2023 /PRNewswire/ The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Adoption

United statesChristophe bourdonFilippa stenbergAnnette clancyAnders ullmanHelena saxonBo jesper hansenNomination committeeManagement programmeEmployee programmeSobi investor relations teamStaffan schJesper hansenAll employee programmeMall employeeNorth america

Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting , to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev. | March 30, 2023

Vastra gotalands lanUnited statesThomas ehlinVerona pharmaChristophe bourdonBaxter bioscienceLeo pharmaHelena saxonAnnette clancyMannheimer swartling advokatbyrGrev turegatanNycomed takedaFilippa stenbergAnders ullmanLennart franckeBo jesper hansen

Swedish Orphan Biovitrum : 22 March – Phase 3 study results SEL-212 (transcript)

You efficacy and point and we re highly statistically significant, which of course is the first thing. 0:0:6.780 > 0:0:37.30 Peter. | March 27, 2023

City ofUnited kingdomAnders ullmanThomas kudsk larsenTania gonzalez riveraPeter traberDeutsche bankUllman tolerabilityKudsk larsen canKudsk larsen youSwedish orphan biovitrum ab publ stock exchangePress releaseIrst sobi se0000872095

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (2)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB (3)

75% of subjects in the DISSOLVE I extension phase on active treatment were responders through 12 months of.

United statesCarsten brunnAnders ullmanThomas kudsk larsenheadSelecta biosciencesGuido oelkersPeter traberPrnewswire selecta biosciences incSobi investor relations teamExchange commissionCompany immSelecta biosciences incHead of research developmentChief medical officerChief executive officerMedical affairs

vimarsana © 2020. All Rights Reserved.